CD274 and non-small cell lung carcinoma: 3) The overall diagnostic sensitivity and specificity analyses indicates that the relative analytical sensitivities of the Food and Drug Administration-approved kits for tumor cell scoring, most specifically in non-small cell lung cancer, are as follows: Ventana PD-L1 (SP142) << PD-L1 IHC 22C3 pharmDx < PD-L1 IHC 28-8 pharmDx < Ventana PD-L1 (SP263).